Overview

This trial is active, not recruiting.

Conditions osteoarthritis, rheumatoid arthritis, post-traumatic arthritis, ununited humeral head fracture, irreducible 3-and 4-part proximal humeral fractures, avascular necrosis, gross rotator cuff deficiency, failed total shoulder arthroplasty (both glenoid and humeral components require revision
Treatment trabecular metal reverse shoulder system
Sponsor Zimmer, Inc.
Start date January 2011
End date December 2026
Trial size 200 participants
Trial identifier NCT01480440, CMU2010-28E

Summary

The objectives of this study are to obtain survival and outcome data on the Trabecular Metal Reverse Shoulder System when used in primary or revision reverse total shoulder arthroplasty.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective
Arm
Patients requiring primary or revision reverse total shoulder arthroplasty who receive the Trabecular Metal Reverse Shoulder System
trabecular metal reverse shoulder system TM Reverse Shoulder System
Trabecular Metal Reverse Shoulder System used in primary or revision total shoulder arthroplasty

Primary Outcomes

Measure
Survivorship
time frame: 10 Years

Secondary Outcomes

Measure
Pain and Functional Performance
time frame: 10 Years

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Patient is > 18 years of age; - Patient is skeletally mature; - Patient qualifies for primary or revision unilateral or bilateral reverse total shoulder arthroplasty based on physical exam and medical history including the following: osteoarthritis, rheumatoid arthritis, post-traumatic arthritis, ununited humeral head fracture, irreducible 3-and 4-part proximal humeral fractures, avascular necrosis, gross rotator cuff deficiency or failed total shoulder arthroplasty (both glenoid and humeral components require revision); - Patient is willing and able to provide written informed consent; - Patient is willing and able to cooperate in the required post-operative therapy; - Patient is willing and able to complete scheduled follow-up evaluations/questionnaires as described in the Informed Consent; - Patient has participated in the Informed Consent process and has signed the IRB/ERB approved informed consent. Exclusion Criteria: - The patient is a prisoner; - The patient is mentally incompetent or unable to understand what participation in the study entails; - The patient is a known alcohol or drug abuser; - The patient is anticipated to be non-compliant; - The patient has one of the following compromising the affected limb: a significant injury to the upper brachial plexus, paralysis of the axillary nerve or a neuromuscular disease compromising the affected limb which would render the procedure unjustifiable; - The patient has a local/systemic infection; - The patient is known to be pregnant; - The patient has marked bone loss; - The patient has a known sensitivity or allergic reaction to one or more of the implanted materials; - The patient is unwilling or unable to give consent or to comply with the follow-up program.

Additional Information

Official title Prospective Post Market Clinical Follow-up Study of the Zimmer Trabecular Metal Reverse Should System
Description The objectives of this study are to obtain survival and outcome data on the Trabecular Metal Reverse Shoulder System when used in primary or revision reverse total shoulder arthroplasty. This will be done by analysis of standard scoring systems, radiographs and adverse event records. Data will be collected and analyzed to monitor pain, function, and survivorship and to confirm the performance of the Trabecular Metal Reverse Shoulder System. Performance will be evaluated by monitoring the frequency and incidence of adverse events as well as by assessment of the overall pain and functional performances, survivorship, health status and radiographic parameters of all enrolled study subjects who receive the Trabecular metal Reverse Shoulder System. Pain and functional performance will be measured using the American Shoulder and Elbow Surgeons (ASES) Shoulder Assessment and the Single Assessment Numeric Evaluation (SANE), survivorship will be based on removal or intended removal of the device, health status will be determined by evaluation of the SF-12 as well as AEs and radiographic parameters analysis of x-rays.
Trial information was received from ClinicalTrials.gov and was last updated in May 2016.
Information provided to ClinicalTrials.gov by Zimmer, Inc..